Welcome to the all-new Vetlearn

  • Exciting News Coming to Vetlearn in August 2014!
    Coming soon you'll be able to access...
  • Nearly 5,000 Compendium and Veterinary
    Technician
    articles
  • Thousands of industry Conference Proceedings
  • All-new articles (CE and other topics) for the
    entire healthcare team
  • Over 500 hours of interactive CE Videos
  • An engaging new community for asking
    questions, making connections and more!

To access Vetlearn, you must first sign in or register.

registernow

  • Registration for new subscribers will open in August 2014!
  • Watch for additional exciting news coming soon!
Become a Member

Reference Desk March 2013

Pallimed Solutions, Inc. Announces Voluntary Nationwide Recall

    March 25, 2013 — Pallimed Solutions, Inc. of Woburn, MA, doing business as Pallimed Pharmacy, is voluntarily recalling all sterile compound products dispensed since January 1, 2013 to the user level.

    The recall resulted from a recent inspection conducted by the U.S. Food and Drug Administration and the Massachusetts Board of Registration in Pharmacy where visible particulates (filaments) were observed in vials of sterile compounded products: TRIMIX, BIMIX (Lot 02252013@3), ALPROSTADIL, DMSO 50 PERCENT – IRRIGATION (Lot 03122013@19), and BACTERIOSTATIC WATER FOR INJECTION (Lot 01072013@28). The potential public health risks are unknown as the particulate matter has not yet been identified.  However, particulate matter has the potential to damage or obstruct blood vessels, which could induce emboli, cause systemic allergic reaction, or cause tissue responses to the foreign material.

    At this time a total of 5 affected vials were discovered.  To date, no injuries or illnesses have been reported.  In an abundance of caution, the pharmacy included all sterile compounded products dispensed since January 1, 2013, in the voluntary recall.  The company took the precautionary recall measure to ensure patient safety.

    The products are used for a wide range of therapeutic uses, including for treatment of erectile dysfunction, testosterone replacement therapy, vitamin injections, and ophthalmic preparations. All products are packaged in glass vials. All products were distributed to patients and/or physicians’ offices through Friday, March 22, 2013, from Woburn, Massachusetts.

    The recall applies to the following sterile compound products dispensed since January 1, 2013, including all strengths, all dose forms, and all products within expiry date:

    ACETYLCYSTEINE OPHTHALMIC SOLUTION
    ALPROSTADIL IN NS INJECTION
    ATROPINE INJECTION
    BACTERIOSTATIC WATER FOR INJECTION BIMIX INJECTION
    BUPRENORPHINE HCL, VETERINARY INJECTION
    CIDOFOVIR OPH SOLUTION
    CYCLOSPORINE OPHTHALMIC
    DIAZEPAM INJECTIBLE
    DEXAMETHASONE PF
    DMSO AQUEOUS IRRIGATION 50%
    GENTAMICIN SULFATE IRRIGATION
    HCG CHORIONIC GONADOTROPIN
    HYDROXYPROGESTERONE CAPR. (G.S.)
    METHYLCOBALAMIN - PF
    MIC WITH B6 & B12
    NANDROLONE DECANOATE INJECTIBLE
    QUADMIX INJECTION
    TACROLIMUS OPHTHALMIC
    TESTOSTERONE CYPIONATE/TESTOSTERONE ENANTHATE INJECTION
    TESTOSTERONE CYPIONATE/PROPIONATE INJECTION
    TESTOSTERONE CYPIONATE INJECTION
    TRIMIX INJECTION
    VANCOMYCIN OPTHALMIC P.F.
    VERAPAMIL INJECTION

    Products were distributed directly to patients and/or physicians’ offices located in some or all of the following states: California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maine, Maryland, Massachusetts, Michigan, Nevada, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Tennessee, Texas, Vermont, Virginia, and Wisconsin.

    Users or recipients should discontinue use and return the recalled products to Pallimed.  All users who received any of the recalled products have been or will be notified by telephone, fax, electronic mail and/or regular mail of the recall.

    To return product, request assistance, or report complaints related to this recall, users should contact Pallimed at  www.pallimed.com and by telephone at (781) 937-3344, Monday through Friday, between 10:00 a.m. and 5:00 p.m.

    Adverse events that may be related to the use of these products may be reported to FDA’s
    MedWatch Adverse Event Reporting Program either online, by regular mail or by fax:

    Pallimed deeply regrets the impact this recall notice imposes on our customers. We will continue to do everything possible to ensure patient safety and comply with all government standards and requirements.

    This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

    Source: FDA

    didyouknow

    Did you know... Although pet owners' top worries revolve around their pets' health and wellness only 34% rated their knowledge of what's best for their pet's health as excellent. Read More

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More
    Subscribe